Call for Applications for MSHP Executive Vice President

The Michigan Society of Health-System Pharmacists is currently seeking to fill the position of MSHP Executive Vice President (EVP). The EVP must be a member of the Michigan Pharmacists Association, MSHP and the American Society of Health-System Pharmacy with a health-system background and practice knowledge who is a licensed to practice pharmacy in Michigan and in good standing.

The responsibilities of the EVP are outlined in the application, which is attached to and downloadable from this posting. Compensation for serving as the MSHP EVP includes complimentary registration and travel expenses to the ASHP’s Summer Meeting and Midyear Clinical Meeting each year, overnight accommodations prior to the MSHP Annual Meeting and a monthly stipend. The EVP is considered an independent contractor, contracted by the MSHP Board of Directors for a three-year period.

Individuals interested in being considered for the EVP position should complete an application and submit their resume or curriculum vitae to MSHP President Stacy Brousseau via email with the subject line “MSHP EVP.” Submissions must be received no later than Friday, March 28, 2025. Applicants will be evaluated and the most qualified individuals will be scheduled for an interview no later than Friday, April 25, 2025.

Questions may be directed to MSHP President Stacy Brousseau (brousses@bronsonhg.org) or current MSHP EVP Ed Szandzik (eszandz2@gmail.com).

Don't Forget to Register for ACE 2025!

Remember to register for the 2025 Annual Convention & Exposition! ACE 2025 is the premier pharmacy continuing education event in Michigan, taking place April 11-13, 2025, at the Grand Traverse Resort and Spa. To view the full table of convention pricing, click here.

We encourage our members to make the 2025 ACE their "stay-cation" – golf, water activities and wineries are just a few things you can do in beautiful Traverse City. After you register for ACE 2025, be sure to book your room at the Grand Traverse Resort. Room reservations need to be made by March 10, 2025, to receive the MPA block rate, so act now! Click the booking link below or call 231-534-6001 to speak with a reservations agent. Attendees will receive the discounted rate if they mention the Michigan Pharmacists Association.

- BOARD UPDATE -

How to “Empower, Engage, Enact”

in the Ambulatory Care Setting

By Nada Farhat, Pharm.D., BCPS, BCACP;

clinical pharmacist specialist, Michigan Medicine; MSHP president-elect

As I reflect upon the past successful year and ponder the 2025 theme for MSHP — “Empower, Engage, Enact” — I immediately envision how this applies to the ambulatory care setting, which has evolved over the years, but has the potential for continued advancement through further empowerment, advocacy and most importantly, through action.

Although the disease states vary from practice to practice, there are several common elements that pharmacists must be aware of to practice successfully in this setting. The MSHP Ambulatory Care Committee has developed a comprehensive resource, the Ambulatory Care Survival Guide, which may be useful in equipping pharmacists with the knowledge and skills necessary to perform at the top of their license. This guide provides information about establishing an ambulatory care pharmacy service, strengthening clinical practice, developing business models and staying up-to-date with provider status information and billing opportunities.

While the focus is on empowering pharmacists, it is also imperative to consider empowering patients, especially in the ambulatory care setting. This is particularly important when managing patients with chronic diseases, which may require various strategies to equip them with the necessary knowledge, skills and resources to improve their health. Traditional medication counseling may need to be paired with health coaching and motivational interviewing to generate long-term action toward patient goals.¹ Ambulatory pharmacists play a key role in implementing these approaches that will ultimately influence behavior change, leading to positive outcomes related to chronic disease management.²

Once pharmacists are empowered with the skills and knowledge necessary to improve patient care, engaging other health care providers within the practice is vital. Many times, sustaining an ambulatory care practice may be more challenging than initially establishing the practice if other health care professionals and stakeholders are not involved in the practice development. Furthermore, it is equally important to engage community stakeholders and relevant health care organizations that can further support patient care outside of the traditional clinic setting.

Pharmacists who are empowered and engaged within their practice sites and communities is just the start. We must encourage them to enact – take actionable steps toward implementing changes they wish to see. This should occur not only at a practice level, but should be shared across the broader health care system. For example, a pilot project focusing on antibiotic resistance could also impact health system policies and guidelines and could help improve statewide resistance patterns. These findings should ideally be published to empower other ambulatory pharmacists and health care systems locally, statewide and nationally. Resources through MSHP and the American Society of Health-System Pharmacists could also connect practitioners to share these best practices, ultimately fulfilling the theme of “Empower, Engage, Enact.”

Lastly, the MSHP Ambulatory Care Committee is focused on improving advocacy efforts, specifically for ambulatory care pharmacists. This includes developing an advocacy video that can be shared with health care professionals, stakeholders and legislators to help them better understand these pharmacists' important roles within their institutions and communities. Future MSHP Monitor articles will highlight additional opportunities to work together to “Empower, Engage, Enact” – creating a stronger foundation, forming more powerful relationships and ultimately impacting patient care in a meaningful way.

References

1. Lonie JM, et al. Pharmacist-based health coaching: A new model of pharmacist-patient care. Res Social Adm Pharm. 2017;13(3):644-652. 
2. Barbosa HC, et al. Empowerment-oriented strategies to identify behavior change in patients with chronic diseases: An integrative review of the literature. Patient Educ Couns. 2021;104(4):689-702.

- ANTIMICROBIAL STEWARDSHIP -

Growth and Expansion of the CHARM Project

By Cameron Lakatos, CHARM intern, Pharm.D. candidate, class of 2026; Minji Sohn, PhD.; Benjamin Pontefract, Pharm.D.; Kushal Dahal, MS; Michael E. Klepser, Pharm.D, FCCP, FIDP; Ferris State University College of Pharmacy

The Collaboration to Harmonize Antimicrobial Registry Measures (CHARM) Project was developed in 2015 as a student-led project at a single clinic to track outpatient antibiotic use. CHARM has since evolved into an academic/public health partnership that has dramatically impacted outpatient antimicrobial stewardship efforts not only in Michigan, but nationwide.

Initial efforts were funded by the Michigan Department of Health and Human Services and offered a means for health systems to track outpatient antibiotic use in medical clinics and assess the appropriateness of the use of oral antibiotics. Additionally, CHARM provided a standardized approach that allowed for partnering health systems to benchmark utilization to state-wide metrics. In 2020, the Joint Commission developed performance measures for outpatient clinics, whereby clinics are scored on if they track and report outpatient antibiotic use.

When this occurred, CHARM stepped up and has now expanded its partnerships to include more than 23 health systems of all sizes and in all regions of the state. CHARM have been capturing a growing amount of data surrounding outpatient oral prescriptions in the state and provides participating systems with interactive dashboards to assist with identifying, tracking impact and justifying outpatient antimicrobial stewardship efforts. All of these services are provided at no cost to the health system so that the spared resources can be utilized to support other stewardship initiatives.

CHARM works with partners to create interactive dashboards allowing them to assess historical and current antimicrobial use patterns at the system-wide level down to the prescriber levels. Dashboards help users pinpoint areas and individuals where interventions may be warranted.  Data for CHARM is collected in collaboration with information technology groups at each partnering site to develop a strategy that is secure, timely and associated with a low workload for the system. As a result, most systems receive monthly updates on their antimicrobial usage, which allows clinicians to have highly granular, actionable data at their fingertips in a timely manner.

In addition to supporting partner outpatient stewardship initiatives, CHARM has worked with health system partners and Blue Cross Blue Shield of Michigan to develop the ability to estimate health system and provider progress towards meeting several infectious diseases-related Healthcare Effectiveness Data and Information Set measures. This advancement helps clinicians and health system administrators assess the monetary benefits that outpatient AMS provides their systems. The CHARM team has also been working towards the capability of generating peer-to-peer antibiotic utilization reports that would allow for clinician prescribing patterns to be compared to individual, clinic, system or state-wide peers.

All of this work has attracted interest from the Centers for Disease Control and Prevention and from public health agencies and health systems across the nation. CHARM now partners with health systems in nine states and one Indian nation. Recently, an agreement was finalized that will allow CHARM to obtain support from the Illinois Department of Public Health to offer inclusion in CHARM to all medical clinics in Illinois. Similar discussions are underway with a number of other state public agencies across the country.

In addition to its use in human medical clinics, CHARM has expanded its antimicrobial use tracking and reporting capabilities to include dental practices through partnerships with Ohio State University and the University of Connecticut and animal hospitals and clinics through collaborations with the Michigan State School of Veterinary Medicine and Chicago Health Department. These advancements would make CHARM the most comprehensive source for monitoring outpatient antimicrobial available today.

CHARM remains committed to the importance of outpatient antimicrobial stewardship and highlights the importance of the concept of One Health. CHARM continues to work towards bringing new innovations and discoveries to the collective knowledge of health care and outpatient antimicrobial stewardship. We are largely dependent on the willingness of health systems and those with an interest in improving outpatient antibiotic use help us forge these partnerships.

As a result, we need to continually establish new contacts to expand the value of the program. Our goal is to capture data on 80% of all antimicrobials prescribed in outpatient clinics in Michigan. However, health system mergers, competing priorities within health systems and limited resources within small/independent practices continue remain significant obstacles. We request the continued support of MSHP and its members to help educate their practice sites about CHARM and help us identify contacts within these practices to allow us to demonstrate the value of CHARM. If you have any questions related to CHARM or would like to arrange a demonstration of CHARM for your health system/clinic please email Michael Klepser at michaelklepser@ferris.edu.

- STUDENT FOCUS -

3 Tips for P3s: How to Have a Successful P4 Year

By Lily Kim, Pharm.D. candidate 2025, University of Michigan College of Pharmacy

After completing my P3 year I was very anxious and excited to begin my P4 year and APPE rotations. After countless assignments, quizzes and exams for the past three years, it was finally time to apply my knowledge in practice. However, this also meant that I was now subject to higher expectations from preceptors and did not have 80 classmates around me to ask questions, which made me nervous.

While I had received advice from previous preceptors and upperclassmen and knew what to expect, there still were certain aspects that I did not truly appreciate until I was on my APPE rotations myself. As P3s are now only one semester away from starting their APPE rotations, here are three tips to keep in mind in order to have a successful and rewarding P4 year.

1. Be proactive, plan ahead and stay organized. Although each rotation is different, there often are multiple projects that your preceptor assigns to you in addition to “regular” rotation work, such as journal clubs and topic presentations. In addition, on top of APPE-related tasks, there are many other moving parts during the P4 year, such as residency or fellowship applications, co-curricular activities and national poster presentations. With so many things going on at the same time, it is very easy to forget important deadlines and rush into completing tasks. Make sure to look ahead in your calendar, mark important dates and set smaller goals regularly instead of procrastinating until the deadline.
2. It is also very important to communicate well with your preceptor. Every student has a different background, interests and goals, and preceptors will not know about them unless you tell them. Don’t be afraid to ask questions, tell them if you would like to know more about a specific topic and, most importantly, talk to them early on about any difficulties that you are having during your rotation. Most preceptors that I have met are more than willing to help you in any way for you to make APPE rotations as fulfilling and enjoyable as possible. Don’t wait until your preceptor notices your problem to solve it.
3. Lastly, it is normal to feel like you don’t know enough, especially in the beginning of each block. I remember being so upset while working up patients for the first time during my general medicine rotation, because three patients took me almost three hours. I also felt like I had to move onto my next block just as I was starting to feel comfortable and confident at what I was doing. With only a few weeks in each block, it is normal to feel like this and preceptors don’t expect you to perform at 100% capacity from the beginning. Find out which area you are struggling in and ask a lot of questions to your preceptors; you will get better and feel more confident as you get more experience.

Even though my P4 year has not been easy, I have thoroughly enjoyed my APPE rotations and have grown personally and professionally. I hope these tips help the current P3s in having a smooth transition into their APPE rotations and having a rewarding P4 year.

- RESIDENT"S CORNER -

Striking a BALANCE: Examining the New Study Evaluating Treatment Regimens for Bacteremia

By Octavia Valencia, Pharm.D., Erik Gotberg, Pharm.D., and Raneem Sannah, Pharm.D., PGY1 pharmacy residents, Corewell Health Grand Rapids

Antibiotic resistance is a significant threat to public health as it continues to increase in prevalence. In the United States alone, more than 2.8 million antimicrobial-resistant infections occur annually, resulting in over 35,000 deaths.¹ Additionally, the Centers for Disease Control and Prevention reported increases in six bacterial antimicrobial-resistant hospital-onset infections from 2019 to 2022, including carbapenem-resistant Enterobacterales, extended-spectrum beta-lactamase -producing Enterobacterales and multidrug-resistant Pseudomonas aeruginosa.²

Increased resistance is driven by many factors, but is mainly attributed to the use of antibiotics in general. As antibiotics are increasingly prescribed, selective pressure forces microorganisms to adapt, resulting in development of resistance mechanisms that protect them from the detrimental effects of antibiotics. Thus, it is important to decrease use of antibiotics to slow the development of antibiotic resistance. One way this can be done is by decreasing antibiotic prescribing; however, it is not feasible to avoid the use of antibiotics in patients with proven bacterial infections.

Decreasing the duration of antibiotic therapy has been proposed as an alternative strategy to slow the development of resistance. More than 45 randomized controlled trials from recent years have demonstrated no difference in efficacy between traditional and shorter courses of antibiotic treatment for multiple infection types, including but not limited to, pneumonia (community- and hospital-acquired), osteomyelitis, urinary tract infections, intra-abdominal infections and Gram-negative bacteremia.³ With this in mind, it makes sense to combat antibiotic resistance by limiting antibiotic treatment duration.

Bloodstream infections are a common cause of mortality and morbidity in hospitalized patients. With the rising incidence of multidrug-resistant organisms, pharmacists have a critical role in advocating for proper antibiotic stewardship in patients with bacteremia. Historically, data has been limited regarding duration of therapy for antibiotics. Current IDSA Surviving Sepsis guidelines are non-specific on duration of therapy and state that for patients with bacteremia, many factors need to be considered in determining the duration of therapy and if possible, the shortest duration should be used. Duration of therapy for patients with gram negative bacteremia has ranged from as low as five days in clinically stable patients to 14 days in clinically unstable patients. Given the limited data, many patients receive 14 days of antibiotics. More evidence is needed to properly treat patients with bacteremia.⁴

One of the first large, randomized controlled trials that examined duration of therapy specifically for bacteremia, was published in 2019 titled “Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial.” This trial took place in Israel and Italy and found that an antibiotic duration of seven days was non-inferior to a 14-day duration according to their composite outcome of mortality, clinical failure, readmissions or extended hospitalizations at 90 days.⁵ 

However, in November of this year the BALANCE trial, which took place in Australia, New Zealand, Switzerland, Canada, South Africa and the United States, was published.⁶ Although both studies sought and demonstrated that a seven-day course of antibiotics for bacteremia was non-inferior to a 14-day regimen, there are some key differences between the two that change the extent to which either can be extrapolated to certain patient populations and disease states. Primarily, Yahav et al. 2019 included patients who were considered hemodynamically stable and afebrile for 48 hours prior to and seven days after randomization and treatment.⁵ The trial exclusively included uncomplicated gram-negative blood stream infections. The authors of the BALANCE trial included both gram negative and gram-positive bacteremia with some exclusions of certain organisms, most notable Staphylococcus aureas.⁶ They also expanded patient eligibility by not including the criteria of hemodynamic stability and afebrile for 48 hours prior to randomization and a larger demographic pool by including data from centers in six different countries from the previous study.

Secondly, the BALANCE trial detailed which antibiotics specifically were used whereas Yahav et al. 2019 listed antibiotic classes. When looking specifically at the breakdown of which antibiotics were used, both trials utilized cephalosporins and beta lactam/beta lactam + beta lactamase inhibitors as the pillars of therapy. The 2019 study breaks down which antibiotic classes were used most frequently enterally or through IV and found fluoroquinolones were the mainstays of treatment when transitioning to oral therapy. In contrast, the BALANCE does not differentiate between enteral or IV administration. Therefore, Yahav et al. 2019 can be relied upon when assessing efficacy and safety of transitioning from IV treatment to oral medications in that particular patient population. Overall, the BALANCE trial expands clinical applicability by increasing the patient inclusion criteria to include both gram-negative and gram-positive causes of bacteremia and patients who were not hemodynamically stable.

Although increasing evidence has emerged in support for shorter antibiotic treatment regimens to decrease cost of patient care, improve mortality and morbidity rates, and support antimicrobial stewardship, it is still limited to certain infections and patient populations. The BALANCE trial expanded upon what Yahav et al. 2019 brought forward when looking at a seven- versus 14-day antibiotic treatment for bacteremia. Both trials demonstrated that a seven-day antibiotic regimen is non-inferior to 14 days. While implementation of this new data into official guidelines will take years to be seen, the practice can begin now.

In true antibiotic stewardship fashion, specific patient clinical factors will continue to guide our assessments and recommendations. Not addressed in either article is the importance of the specific oral beta-lactam chosen and the relative dosing of the agent. These two factors may have a significant impact on the total duration of therapy in addition to mortality and morbidity-based end points. For pharmacists, this study arms us with more data to evaluate shorter antibiotic regimen durations in bacteremic patients for safety and efficacy, while adhering to the idea of practicing evidence-based medicine.

References

1. CDC. Antimicrobial Resistance Facts and Stats. Antimicrobial Resistance. Published April 22, 2024. https://www.cdc.gov/antimicrobial-resistance/data-research/facts-stats/index.html
2. CDC. Antimicrobial Resistance Threats in the United States, 2021-2022. Antimicrobial Resistance. Published July 16, 2024. https://www.cdc.gov/antimicrobial-resistance/data-research/threats/update-2022.html
3. Spellberg B, Rice LB. Duration of Antibiotic Therapy: Shorter Is Better. Ann Intern Med. 2019;171(3):210-211. doi:10.7326/M19-1509
4. Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., ... & Levy, M. (2021). Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Critical care medicine, 49(11), e1063-e1143.
5. Yahav D, Franceschini E, Koppel F, et al. Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. Clin Infect Dis. 2019;69(7):1091-1098. doi:10.1093/cid/ciy1054
6. BALANCE Investigators, for the Canadian Critical Care Trials Group, the Association of Medical Microbiology and Infectious Disease Canada Clinical Research Network, the Australian and New Zealand Intensive Care Society Clinical Trials Group, and the Australasian Society for Infectious Diseases Clinical Research Network, Daneman N, Rishu A, et al. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N Engl J Med. Published online November 20, 2024. doi:10.1056/NEJMoa2404991

- MEMBER SPOTLIGHT -

Marc Guzzardo

Director of Pharmacy and Support Services, Henry Ford Health-Genesys Hospital

Member Since: More than 30 years ago

Describe Your Role/Day in the Life: As the director of pharmacy, I have the privilege of leading teams of high-skilled professionals delivering quality services to enhance the lives of the people in our community. Providing services to our community members creates opportunities for pharmacy professionals on the teams to learn, grow and advance their careers. I have the opportunity to work with students, residents, technicians, faculty, pharmacists and leaders working together toward a common vision that supports our patient care initiatives and personal goals. It is a pleasure to serve as a leader to establish a strategic vision and help each individual contribute to the team's success.  

Why You’re an MSHP/MPA Member: The practice of pharmacy is in many ways dictated at the state level. It is the MPA, and its practice sections such as MSHP that help shape the practice of pharmacy in the state of Michigan. MPA has robust government affairs, advocacy and professional practice activities supporting all pharmacists and technicians in the state. Without MPA, Michigan pharmacists and technicians would have a large void in representation in Lansing. I am glad to know that my membership dues support MPA advocating for all of us and create opportunities for us to learn, grow and collaborate.

On a more personal level, I have met scores of pharmacists and technicians around the state through my participation with MPA/MSHP. Knowing these people, many of whom have become friends, has enriched my life and I am grateful for the opportunity to meet them through MPA/MSHP. 

Recent Accomplishments: I am fortunate to have served on the MSHP Executive Board as treasurer and the MPA executive board as treasurer. Yes, I like finance. These two professional activities, along with accomplishments at my practice site allowed me to qualify for the Certified Pharmacy Executive Leader credential from ASHP.

How MSHP/MPA Has Helped You Achieve Any Accomplishments: Several years ago, I wanted to start a new residency program. I attended a session at the MSHP Annual Meeting about starting new residency programs. I also contacted the MSHP residency committee chair. I was given multiple resources, including information documents and spreadsheet templates to use to measure the financial impact of a residency program. With the aid of these resources and the ability to contact MSHP members for advice, I was able to establish a new residency program that has grown to two separate resident programs for five residents.  

- REGIONAL UPDATE -

Western Michigan Society of Health-System Pharmacists (WMSHP)

By Ben Pontefract, Pharm.D., BCPS, associate professor,

Ferris State University; WMSHP immediate past president

The Western Michigan Society of Health-System Pharmacists had a successful 2024 and is ready to tackle 2025. Since our last update, our team has been hard at work coordinating events and making plans for the future. Starting in October, we hosted our annual Residency Showcase, where we had our biggest turnout ever (even if it was only by three attendees)! Thank you, e-board members Kyle Brillantes, Shelby Kelsh, Tara McAlpine and Jeff VanHouten, for helping me make sure that event ran smoothly, and thank you to Ferris State University for hosting! October also saw the return of our in-person and virtual mock interviews. Thank you to all of our volunteer interviewers and a special thank you (again!) to Tara McAlpine for putting the event together.

WMSHP Residency Showcase, Oct. 1, 2024.

WMSHP was also able to continue providing monthly continuing education presentations for our members. Our September meeting was coordinated by Jeff VanHouten and featured Sarah Leonard, former WMSHP president, as our speaker. Leonard presented on the use of enneagrams to help with interprofessional team building and communication. While not a clinical topic, this talk was incredibly relevant in terms of understanding the people who we work with on a deeper level.

Our October meeting was coordinated by Nathan Kanous and featured Emily Ernst, who presented on the latest data surrounding pharmacogenomics. As an infamous pharmacogenomics doubter, I was impressed by the data she shared! Finally, our November meeting was coordinated by Kristina Stoncius and featured Dr. Devon Stonerock who presented on CAR-T Cell therapy. I found his insights on how to manage patients receiving these therapies was incredibly useful, as someone with little knowledge of the field.

Dr. Sarah Leonard, Pharm.D., delivered a CE titled “Professional Development: Utilizing the Enneagram to Better Understand Yourself and Your Colleagues,” Sept. 12, 2024.

Looking to the future, I am happy to announce WMSHP’s newly-elected executive board members. Continuing in their same positions from last year are Kristina Stoncius, general board member and Brad Miller, secretary. They will be joined by Bryan Homberg and Megan Van Baren, who are brand-new board members. We also have Ashley Blanchette moving from general board member to president-elect and Jessie Prociv moving into the president role. While I will no longer be president, I will continue serving next year as the Immediate Past President. It’s sad to be stepping down, but I am sure Jessie will do a fantastic job moving WMSHP forward!

Last, but not least, I would like to announce a new (hopefully annual) event. Our March 2025 meeting will be WMSHP’s Student Research Night! Throughout the next few months, we will be accepting applications from students who are interested in presenting their research to our members. This event will still be worth continuing education credit and will be coordinated by board member Guadalupe Chavez. If you know any students who completed research this past year who are looking for presentation experience, send them our way!

As always, feel free to email me at pontefb@ferris.edu with any questions or ideas. Thank you all for the wonderful year as WMSHP president and I look forward to seeing everyone in unofficial capacities in the future!

CE Speaking Opportunities at Non-Pharmacy Organizations

The MSHP Publications Committee was charged in 2024 with identifying opportunities for pharmacists to present at non-pharmacy organization meetings. After surveying MSHP membership in April, the committee compiled a list of organizations. Click the button below if you're interested in presenting.

OFFICERS

PRESIDENT | Stacy Brousseau | 269-341-7407 | Bronson Methodist Hospital, Kalamazoo

PRESIDENT-ELECT | Nada Farhat | nmhammou@med.umich.edu | Michigan Medicine, Ann Arbor

IMMEDIATE PAST PRESIDENT | Kyle Schmidt | 616-685-6675 | Mercy Health St. Mary's, Grand Rapids

TREASURER | Michelle Dehoorne | 313-343-6381 | Ascension, Detroit

EXECUTIVE VICE PRESIDENT | Edward Szandzik | 313-587-6279 | Detroit

DIRECTORS

Tara McAlpine | tara.mcalpine@trinity-health.org | Trinity Health Michigan

Ben Pontefract | bpontefract@gmail.com | Ferris State University, Big Rapids

Julie Schmidt | 269-341-7999 | Bronson Methodist Hospital, Kalamazoo

Amber Lanae Martirosov | 313-916-3494 | Wayne State University, Detroit

REGIONAL SOCIETY REPRESENTATIVES 

CENTRAL | Tim Ekola | 734-845-3418 | VA Ann Arbor Healthcare System

NORTHERN | Miranda Maitland | mirandapmaitland@gmail.com | My Michigan Medical Center, Sault Ste. Marie

SOUTHEASTERN | Lama Hsaiky | lama.hsaiky@corewellhealth.org | Corewell Health, Dearborn

WESTERN | Jessica Prociv | jessie_olds28@yahoo.com | Bronson Methodist Hospital, Kalamazoo

MANAGING EDITOR | Ryan Weiss | (517) 377-0232 | Michigan Pharmacists Association, Lansing

The MSHP Monitor is a publication of the Michigan Society of Health-System Pharmacists, published as a service to its members.

Michigan Society of Health-System Pharmacists - An Affiliated Chapter of the American Society of Health-System Pharmacists and a Practice Section of the Michigan Pharmacists Association